These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24410326)

  • 21. Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists.
    Cohen ML; Mendelsohn LG; Mitch CH; Zimmerman DM
    Receptor; 1994; 4(1):43-53. PubMed ID: 8038706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.
    Carroll FI; Gichinga MG; Kormos CM; Maitra R; Runyon SP; Thomas JB; Mascarella SW; Decker AM; Navarro HA
    Bioorg Med Chem; 2015 Oct; 23(19):6379-88. PubMed ID: 26342544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.
    Carroll FI; Chaudhari S; Thomas JB; Mascarella SW; Gigstad KM; Deschamps J; Navarro HA
    J Med Chem; 2005 Dec; 48(26):8182-93. PubMed ID: 16366600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.
    Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y
    Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity.
    Gengo PJ; Pettit HO; O'Neill SJ; Wei K; McNutt R; Bishop MJ; Chang KJ
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1221-6. PubMed ID: 14534368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
    Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
    J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor.
    Stevens WC; Jones RM; Subramanian G; Metzger TG; Ferguson DM; Portoghese PS
    J Med Chem; 2000 Jul; 43(14):2759-69. PubMed ID: 10893314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
    Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
    J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel cyclic enkephalin analogue with potent opioid antagonist activity.
    Weltrowska G; Lu Y; Lemieux C; Chung NN; Schiller PW
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4731-3. PubMed ID: 15324897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of kappa and delta opioid receptors in isolated organs by using type/subtype selective agonists and antagonists.
    Makó E; Rónai AZ
    Med Sci Monit; 2001; 7(3):350-6. PubMed ID: 11386008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.
    Salvadori S; Attila M; Balboni G; Bianchi C; Bryant SD; Crescenzi O; Guerrini R; Picone D; Tancredi T; Temussi PA
    Mol Med; 1995 Sep; 1(6):678-89. PubMed ID: 8529134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
    Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
    Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic kappa address element to the delta antagonist, natrindole: 5'-[N2-alkylamidino)methyl]naltrindole derivatives as a novel class of kappa opioid receptor antagonists.
    Olmsted SL; Takemori AE; Portoghese PS
    J Med Chem; 1993 Jan; 36(1):179-80. PubMed ID: 8380614
    [No Abstract]   [Full Text] [Related]  

  • 34. Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum.
    Gray AC; White PJ; Coupar IM
    Br J Pharmacol; 2005 Mar; 144(5):687-94. PubMed ID: 15678085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.
    Le Bourdonnec B; Barker WM; Belanger S; Wiant DD; Conway-James NC; Cassel JA; O'Neill TJ; Little PJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2006-12. PubMed ID: 18313920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
    Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
    Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
    Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
    J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
    Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
    J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
    Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
    Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.